CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 5970/S28

FINAL PRINTED LABELING

Labeling: ORIGINAL
NDA No: 5970 Rc'd. 9-21-
Reviewed by: James P Hamilton 1/22/88

J-1514e

ESI ELKINS-SINN, INC.

SOTRADECOL®

(Sodium Tetradecyl Sulfate Injection)

For Intravenous Use Only

DESCRIPTION

Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. 7-Ethyl-2-methyl-4-hendecanol sulfate sodium salt:



APPROVED JAN 29 1988

Sotradecol® (Sodium Tetradecyl Sulfate Injection) is a sterile nonpyrogenic solution for intravenous use as a sclerosing agent. Each mL contains sodium tetradecyl sulfate 10 mg or 30 mg, benzyl alcohol 0.02 mL and dibasic sodium phosphate, anhydrous 0.72 mg in Water for Injection. pH 7.0-8.1; monobasic sodium phosphate and/or sodium hydroxide added, if needed, for pH adjustment.

CLINICAL PHARMACOLOGY

Sotradecol® (sodium tetradecyl sulfate) is a mild sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration.

INDICATIONS AND USAGE

Indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks due to conditions such as old age.

CONTRAINDICATIONS

Contraindicated in previous hypersensitivity reactions to the drug; in acute superficial thrombophlebitis; significant valvular or deep vein incompetence; huge superficial veins with wide open communications to deeper veins; phlebitis migrans; acute cellulitis; allergic conditions; acute infections; varicosities caused by abdominal and pelvic tumors unless the tumor has been removed; bedridden patients; such uncontrolled systemic diseases as diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias and acute respiratory or skin diseases.

WARNINGS

Since severe adverse local effects, including tissue necrosis, may occur following extravasation, Sotradecol® (Sodium Tetradecyl Sulfate Injection), should be administered only by a physician familiar with proper injection technique. Extreme care in needle placement and using the minimal effective volume at each injection site are, therefore, important.

Allergic reactions have been reported. Therefore, as a precaution against anaphylactoid shock, it is recommended that 0.5 mL of Sotradecol® be injected into a varicosity, followed by observation of the patient for several hours before administration of a second or larger dose. The possibility of an anaphylactoid reaction should be kept in mind, and the physician should be prepared to treat it appropriately. In extreme emergencies, 0.25 mL of 1:1000 Epinephrine Injection (0.25 mg) intravenously should be used and side reactions controlled with antihistamines.

PRECAUTIONS

GENERAL

Venous sclerotherapy should not be undertaken if tests such as the Trendelenberg and Perthes, and angiography show significant valvular or deep venous incompetence. The physician should bear in mind the fact that injection necrosis is likely to result from extravascular injection of sclerosing agents.

Extreme caution must be exercised in the presence of underlying arterial disease such as marked peripheral arteriosclerosis or thromboangiitis obliterans (Buerger's Disease).

The drug should only be administered by physicians who are familiar with an acceptable injection technique. Because of the danger of thrombosis extension into the deep venous system, thorough preinjection evaluation for valvular competency should be carried out and slow injections with a small amount (not over 2 mL) of the preparation should be injected into the varicosity. In particular, deep venous patency must be determined by angiography and/or the Perthes test before sclerotherapy is undertaken.

Embolism may occur as much as four weeks after injection of sodium tetradecyl sulfate.
The incidence of recurrence is low if the patient wears elastic stockings.

DRUG INTERACTIONS

No well-controlled studies have been performed on patients taking antiovulatory agents. The physician must use judgment and evaluate any patient taking antiovulatory drugs prior to initiating treatment with Sotradecol® (sodium tetradecyl sulfate). (See ADVERSE REACTIONS.)
Heparin should not be included in the same syringe as Sotradecol® since the two are incompatible.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

When tested in the L5178Y TK$^{+/-}$ mouse lymphoma assay, sodium tetradecyl sulfate did not induce a dose-related increase in the frequency of thymidine kinase-deficient mutants and, therefore, was judged to be nonmutagenic in this system. However, no long-term animal carcinogenicity studies with sodium tetradecyl sulfate have been performed.

PREGNANCY

Teratogenic Effects—Pregnancy Category C. Adequate reproduction studies have not been performed in animals to determine whether this drug affects fertility in males or females, has teratogenic potential, or has other adverse effects on the fetus. There are no well-controlled studies in pregnant women, but investigational and marketing experience does not include any positive evidence of adverse effects on the fetus. Although there is no clearly defined risk, such experience cannot exclude the possibility of infrequent or subtle damage to the human fetus.

NURSING MOTHERS

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sodium tetradecyl sulfate injection is administered to a nursing woman.

ADVERSE REACTIONS

Local reactions consisting of pain, urticaria or ulceration may occur at the site of injection. A permanent discoloration, usually small and hardly noticeable but which may be objectionable from a cosmetic viewpoint, may remain along the path of the sclerosed vein segment. Sloughing and necrosis of tissue may occur following extravasation of the drug.
Systemic reactions, except for allergic ones, have been slight. These include headache, nausea and vomiting. Allergic reactions such as hives, asthma, hayfever and anaphylactoid shock have been reported. (See WARNINGS.)
One death has been reported in a patient who received Sotradecol® (sodium tetradecyl sulfate) and who had been receiving an antiovulatory agent.
Another death (fatal pulmonary embolism) has been reported in a 36-year-old female treated with sodium tetradecyl *acetate* and who was not taking oral contraceptives.

DOSAGE AND ADMINISTRATION

For intravenous use only. Do not use if precipitated or discolored. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

Sotradecol® (Sodium Tetradecyl Sulfate Injection)
1%—2 mL DOSETTE® ampuls packaged in 5s (*NDC* 0641-1514-34)
3%—2 mL DOSETTE® ampuls packaged in 5s (*NDC* 0641-1516-34)

STORAGE

Store at controlled room temperature 15°-30°C (59°-86°F).

ANIMAL TOXICOLOGY

The intravenous LD_{50} of sodium tetradecyl sulfate in mice was reported to be 90 ± 5 mg/kg.
In the rat, the acute intravenous LD_{50} of sodium tetradecyl sulfate was estimated to be between 72 mg/kg and 108 mg/kg.
Purified sodium tetradecyl sulfate was found to have an LD_{50} of 2 g/kg when administered orally by stomach tube as a 25% aqueous solution to rats. In rats given 0.15 g/kg in drinking water for 30 days, no appreciable toxicity was seen although some growth inhibition was discernible.

* * * *

Additional package inserts may be obtained by contacting the Professional Services Department.

Revised April 1987

Manufactured by
ELKINS-SINN, INC., Cherry Hill, NJ 08003-4099
A subsidiary of A.H. Robins Company

FINAL PRINTED LABELING

NDA 5-970/S-028

Sotradecol® (Sodium Tetradecyl Sulfate Injection)

March 24, 1988

ORIGINAL
Labeling:
NDA No: 5-970 Rc'd. 3-25-88
Reviewed by: P. Stewart 6/21/88

APPROVED JUN 23 1988

Open—slide tray out →

5 DOSETTE® Ampuls Each contains **2 mL**

NDC 0641-1514-34

SOTRADECOL® 1%
(SODIUM TETRADECYL SULFATE INJECTION)

FOR INTRAVENOUS USE ONLY

Each mL contains sodium tetradecyl sulfate 10 mg, benzyl alcohol 0.02 mL and dibasic sodium phosphate, anhydrous 0.72 mg in Water for Injection. pH 7.0-8.1; monobasic sodium phosphate and/or sodium hydroxide added, if needed, for pH adjustment.

WARNING: Do not use if precipitated.

USUAL DOSE: See package insert.

Store at controlled room temperature 15°-30°C (59°-86°F).

To open ampul, ignore color line; break at constriction.

Caution: Federal law prohibits dispensing without prescription.

Product Code: 1514-34 B-41514b

ESI ELKINS-SINN, INC. Cherry Hill, NJ 08003-4099
A subsidiary of A. H. Robins Company

2 mL DOSETTE® AMPUL
SOTRADECOL®
(SODIUM TETRADECYL SULFATE INJECTION)
FOR IV USE ONLY
DO NOT USE IF PRECIPITATED
1%
kA-1514D
LOT 000000
EXP. 00/00
ELKINS-SINN, INC.
CHERRY HILL, NJ 08003

FINAL PRINTED LABELING

NDA 5-970/S-028

Sotradecol® (Sodium Tetradecyl Sulfate Injection)

March 24, 1988

ORIGINAL
NDA No: 5-970 Rec'd. 3-25-88
Reviewed by: P Stewart 6/24/88

APPROVED JUN 23 1988

Open—slide tray out →

5 DOSETTE® Ampuls Each contains **2 mL**

NDC 0641-1516-34

SOTRADECOL® 3%
(SODIUM TETRADECYL SULFATE INJECTION)

FOR INTRAVENOUS USE ONLY

Each mL contains sodium tetradecyl sulfate 30 mg, benzyl alcohol 0.02 mL and dibasic sodium phosphate, anhydrous 0.72 mg in Water for Injection. pH 7.0-8.1; monobasic sodium phosphate and/or sodium hydroxide added, if needed, for pH adjustment.

WARNING: Do not use if precipitated.

USUAL DOSE: See package insert.

Store at controlled room temperature 15°-30° C (59°-86° F).

To open ampul, ignore color line; break at constriction.

Caution: Federal law prohibits dispensing without prescription.

Product Code: 1516-34 B-41516b

ELKINS-SINN, INC. Cherry Hill, NJ 08003-4099
A subsidiary of A. H. Robins Company

2 mL DOSETTE® AMPUL
SOTRADECOL®
(SODIUM TETRADECYL SULFATE INJECTION)
FOR IV USE ONLY
DO NOT USE IF PRECIPITATED
3% 2 mL
AA-1516D
LOT 000000
EXP. 00/00
ELKINS-SINN, INC.
CHERRY HILL, NJ 08003